Castillo Moraga M J, Turégano-Yedro M, Pallarés-Carratala V
Centro de Salud Sanlúcar Barrio Bajo, Sanlúcar de Barrameda, Cádiz, España.
Centro de Salud Casar, Cáceres, España.
Semergen. 2023 Jun;49 Suppl 1:102020. doi: 10.1016/j.semerg.2023.102020.
The discovery of the nephroprotective role of sodium-glucose cotransporter type 2 (iSGLT2) inhibitor drugs in people with type 2 diabetes mellitus (DM 2) following the results obtained in the respective cardiovascular safety trials led to a change in the approach to diabetic kidney disease in recent years, positioning this group in the first step in the treatment of this comorbidity. The publication of the results of the DAPA-CKD study with dapagliflozin, demonstrating its benefit in slowing the progression of chronic kidney disease (CKD) in patients with and without DM, has opened a new age in the management of this pathology. These drugs are also safe and easy to use for the clinician. This article reviews the management of iSGLT2 in patients with diabetic and non-diabetic CKD.
在2型糖尿病（DM 2）患者中，钠-葡萄糖协同转运蛋白2（iSGLT2）抑制剂药物在各自心血管安全性试验中取得结果后，其肾脏保护作用被发现，这导致近年来糖尿病肾病的治疗方法发生了变化，将该类药物置于治疗这种合并症的第一步。达格列净的DAPA-CKD研究结果发表，证明其对患有和未患有DM的患者延缓慢性肾脏病（CKD）进展有益，开启了这种疾病管理的新时代。这些药物对临床医生来说也安全且易于使用。本文综述了iSGLT2在糖尿病和非糖尿病CKD患者中的管理。
